ULURU Inc. Share Price

Equities

ULUR

US90403T3086

Pharmaceuticals

Market Closed - OTC Markets 14:32:47 15/08/2023 BST 5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for ULURU Inc. -.--% -.--%
Sales 2016 443K 35.43M Sales 2017 717K 57.41M Capitalization 5.93M 475M
Net income 2016 -4M -320M Net income 2017 -1M -80.05M EV / Sales 2016 5.33 x
Net cash position 2016 16.62K 1.33M Net cash position 2017 3.14M 251M EV / Sales 2017 3.89 x
P/E ratio 2016
-0.48 x
P/E ratio 2017
-1.91 x
Employees 2
Yield 2016 *
-
Yield 2017
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
3 years
0.00
Extreme 0
0.58
5 years
0.00
Extreme 0
1.20
10 years
0.00
Extreme 0
16.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 26/02/17
Chief Tech/Sci/R&D Officer 48 30/03/17
Director/Board Member - 30/03/17
Members of the board TitleAgeSince
Chief Tech/Sci/R&D Officer 48 30/03/17
Director/Board Member 56 19/07/15
Chief Executive Officer 47 26/02/17
More insiders
Altrazeal Life Sciences Inc., formerly ULURU Inc., is engaged in offering advanced topical solutions. The Company is a specialty medical technology company that is involved in developing and commercializing wound care and drug delivery systems based on its patented technologies. Its patented technology platforms include Altrazeal and OraDisc. Altrazeal is a new class of material designed to optimize the wound bed environment and accelerate healing. When applied to a moist wound, the powder interacts with the wound exudate and hydrates. OraDisc is a water-erodible pharmaceutical carrier device, the multi-layered device may be applied to mucosal surfaces, and adheres immediately, delivering actives to treat specific localized diseases/disorders. OraDisc technology can deliver drugs systemically across the mucosal surface or for the release of drugs into the oral cavity. The device causes minimum discomfort and provides erosion rates to deliver therapeutics over different time intervals.
More about the company